Showing 5991-6000 of 7756 results for "".
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- Study: Spironolactone May Be an Alternative to Antibiotics for Women With Persistent Acnehttps://practicaldermatology.com/news/study-spironolactone-may-be-an-alternative-to-antibiotics-for-women-with-persistent-acne/2461725/Spironolactone could be a cheap and readily available alternative to antibiotics for women with persistent acne, according to research out of the University of Southampton. The results of the trial appear in the Bri
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub